Evidence map›Paper›PMID 37680115›Full record

ArticleAnnals of hepato-biliary-pancreatic surgery2023

Exocrine pancreatic cancer as a second primary malignancy: A population-based study.

Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sung Chun Cho, Sang-Jae Park, Sun-Whe Kim, Young-Joo Won

Open access · diamondAbstract read
In one paragraph

Article in Annals of hepato-biliary-pancreatic surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mee Joo KangCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-9289-3808
Jiwon LimDivision of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-3322-7792
Sung-Sik HanCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0001-7047-7961
Hyeong Min ParkCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0002-7579-0241
Sung Chun ChoCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0003-2667-4225
Sang-Jae ParkCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0001-5582-9420
Sun-Whe KimCenter for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0001-6315-6019
Young-Joo WonDivision of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0001-9861-6740
National Cancer Center · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds/Aims: Although cancer survivors are at higher risk of developing second primary malignancies, cancer surveillance strategies for them have not yet been established. This study aimed to identify first primary cancers that had high risks of developing second primary exocrine pancreatic cancer (EPC). Methods: Data on individuals diagnosed with primary cancers between 1993 and 2017 were obtained from the Korea Central Cancer Registry. The standardized incidence ratios (SIRs) of second primary EPCs were analyzed according to the primary tumor sites and follow-up periods. Results: Among the 3,205,840 eligible individuals, 4,836 (0.15%) had second primary EPCs, which accounted for 5.8% of the total EPC patients in Korea. Between 1 and 5 years after the diagnosis of first primary cancers, SIRs of second primary EPCs were increased in patients whose first primary cancers were in the bile duct (males 2.99; females 5.03) in both sexes, and in the small intestine (3.43), gallbladder (3.21), and breast (1.26) in females. Among those who survived 5 or more years after the diagnosis of first primary cancers, SIRs of second primary EPCs were elevated in patients whose first primary cancers were in the bile duct (males 2.61; females 2.33), gallbladder (males 2.29; females 2.22), and kidney (males 1.39; females 1.73) in both sexes, and ovary (1.66) and breast (1.38) in females. Conclusions: Survivors of first primary bile duct, gallbladder, kidney, ovary, and female breast cancer should be closely monitored for the occurrence of second primary EPCs, even after 5 years of follow-up.

Indexed as

Bile duct neoplasmsGallbladder neoplasmsIncidencePancreatic neoplasmsSecond primary neoplasm

Identifiers

PMID37680115
PMCPMC10700948
OpenAlexW4386530452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.